ArticleLeukemia2013
Functional characterization of Foxp3-specific spontaneous immune responses.
Article in Leukemia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.Signal transduction and targeted therapy · 2026Review
- Tumor microenvironment antigens.Seminars in immunopathology · 2023Review
- Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells.Journal for immunotherapy of cancer · 2022Article
- Mechanism by which the combination of SjCL3 and SjGAPDH protects against Schistosoma japonicum infection.Parasitology research · 2021Article
- Article
- Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.Cancer immunology, immunotherapy : CII · 2019Review
- The T-win® technology: immune-modulating vaccines.Seminars in immunopathology · 2019Review
- Cancer immune therapy for myeloid malignancies: present and future.Seminars in immunopathology · 2019Review
- T-Cell Immunopeptidomes Reveal Cell Subtype Surface Markers Derived From Intracellular Proteins.Proteomics · 2018Article
- Prophylactic DNA vaccine targeting Foxp3Cancer immunology, immunotherapy : CII · 2018Article
- Anti-regulatory T cells.Seminars in immunopathology · 2017Review
- Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.Journal of the National Cancer Institute · 2015Article
- Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology.Immunologic research · 2014Review
- Review
- Self-reactive T cells: suppressing the suppressors.Cancer immunology, immunotherapy : CII · 2014Review
- FOXP3-specific immunity.Oncoimmunology · 2013Article
- Review
- Article
- Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody.OncoimmunologyArticle
- The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-infiltrating CD4+CD25+ regulatory T cells (Tregs) are associated with an impaired prognosis in several cancers. The transcription factor forkhead box P3 (Foxp3) is generally expressed in Tregs. Here, we identify and characterize spontaneous cytotoxic immune responses to Foxp3-expressing cells in peripheral blood of healthy volunteers and cancer patients. These immune responses were directed against a HLA-A2-restricted peptide epitope derived from Foxp3. Foxp3-reactive T cells were characterized as cytotoxic CD8+ T cells. These cells recognized dendritic cells incubated with recombinant Foxp3 protein indicating that this protein was indeed internalized, processed and cross-presented in the context of HLA-A2. More importantly, however, Foxp3-specific T cells were able to specifically recognize Tregs. Similarly, Foxp3+ malignant T cells established from a Cutaneous T-cell lymphomas (CTCL) patient were readily killed by the Foxp3-specific cytotoxic T lymphocytes. The spontaneous presence of Foxp3-specific cytotoxic T-cell responses suggest a general role of such T cells in the complex network of immune regulation as such responses may eliminate Tregs, that is, suppression of the suppressors. Consequently, induction of Foxp3-specific cytotoxic T-cell responses appears as an attractive tool to boost spontaneous or therapeutically provoked immune responses, for example, for the therapy of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.